Release of HMGB1 in response to pro-apoptotic glioma killing strategies: efficacy and neurotoxicity

PURPOSE: In preparation for a Phase I clinical trial utilizing a combined cytotoxic/immunotherapeutic strategy using adenoviruses expressing Flt3L (Ad-Flt3L) and thymidine kinase (Ad-TK) to treat glioblastoma (GBM), we tested the hypothesis that Ad-TK+GCV would be the optimal tumor killing agent in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Candolfi, Marianela, Yagiz, Kader, Foulad, David, Alzadeh, Gabrielle E, Tesarfreund, Matthew, Muhammad, AKM G, Puntel, Mariana, Kroeger, Kurt M, Liu, Chunyan, Lee, Sharon, Curtin, James F, King, Gwendalyn D, Lerner, Jonathan, Sato, Katsuaki, Mineharu, Yohei, Xiong, Weidong, Lowenstein, Pedro R, Castro, Maria G
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2769255/
https://ncbi.nlm.nih.gov/pubmed/19570774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0155
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados